Jones, Robert M.,Lehmann, Juerg,Chen, Weichao,Edwards, Jeffrey,Marquez, Glen,Morgan, Michael E.,Sadeque, Abu J. M.,Kim, Sun Hee
申请号：
AU2016259322
公开号：
AU2016259322A1
申请日:
2016.11.15
申请国别(地区):
AU
年份:
2016
代理人:
摘要：
#$%^&*AU2016259322A120161201.pdf#####ABSTRACT OF THE DISCLOSURE The present invention relates to the GPR1 19 receptor agonists: 3-fluoro-4-(5-fluoro-6-(4-(3-(2fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)-N,N-dimethylbenzamide； 3fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)N-methylbenzamide； and 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin1-yl)pyrimidin-4-ylamino)benzamide, and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as a single pharmaceutical agent or in combination with one or more additional pharmaceutical agents, such as, a DPP-IV inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of, for example, a disorder selected from: a GPR1 19-receptor-related disorder； a condition ameliorated by increasing secretion of an incretin； a condition ameliorated by increasing a blood incretin level； a condition characterized by low bone mass； a neurological disorder； a metabolic-related disorder； type 2 diabetes； obesity； and complications related thereto.
